ConductScience.org, home

Comparison · NCT02554383-sae

Amoxicillin-clavulanate vs Placebo: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Amoxicillin-clavulanate vs Placebo: serious adverse events. Trial comparisons, record NCT02554383-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02554383-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.0149wilson
Risk in group 2000.0148wilson
Risk difference, group 1 minus group 20-0.01480.0149newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Amoxicillin-clavulanateAmoxicillin-clavulanate (90/6.4 mg/kg/d in 2 divided dosed for 10 days)0254EG000
Group 2PlaceboPlacebo made to match the study antibiotic (will be taken bid orally for 10 days)0256EG001

Harm

What it counts
Total, serious adverse events
Time frame
The monitoring of adverse events (AEs) began on Day 1 (enrollment) and continued through Day 23 (the follow-up visit). All recorded AEs were followed to adequate resolution.

Source ClinicalTrials.gov

Trial

Title
Efficacy of Antibiotics in Children With Acute Sinusitis: Which Subgroups Benefit?
NCT number
NCT02554383
Phases
PHASE3
Conditions
Sinusitis, Respiratory Tract Infections
Interventions
Amoxicillin-clavulanate, Placebo
Lead sponsor
Nader Shaikh
Results first posted
2023-06-08

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02554383-sae